Fidelity Advisor Series Vii · net assets $3.12B · 154 holdings as of July 31, 2026. Monthly N-PORT disclosure: the full book, not just equities.
EC: 95.1% · STIV: 2.7% · EP: 2.0% · DBT: 0.2%
| Month 1 | Month 2 | Month 3 | |
|---|---|---|---|
| Sales | $20.8M | $20.4M | $26.7M |
| Reinvestment | $-8.76 | $0 | $0 |
| Redemptions | $91.2M | $77.1M | $59.5M |
| Net realized gain (non-derivative) | $76.3M | $79.7M | $69.3M |
| Net unrealized appreciation (non-derivative) | $12.6M | $244M | $-89.2M |
The three months of the reporting period, as filed; month 3 ends July 31, 2026.
| Holding | Value | % of net assets |
|---|---|---|
| Eli Lilly And Co EC | $239M | 7.66% |
| Danaher Corp EC | $211M | 6.75% |
| Thermo Fisher Scientific Inc EC | $197M | 6.31% |
| Unitedhealth Group Inc EC | $130M | 4.17% |
| Johnson And Johnson EC | $118M | 3.78% |
| Abbvie Inc EC | $113M | 3.62% |
| Fidelity Revere Street Trust STIV | $79.3M | 2.54% |
| Argenx Se EC | $65.3M | 2.09% |
| Merck And Co Inc EC | $65.1M | 2.09% |
| West Pharmaceutical Svcs Inc EC | $64.2M | 2.06% |
| Ascendis Pharma A/s EC | $61M | 1.95% |
| Alnylam Pharmaceuticals Inc EC | $55.5M | 1.78% |
| Agilent Technologies Inc EC | $54.7M | 1.75% |
| Viatris Inc EC | $52M | 1.67% |
| Natera Inc EC | $51.5M | 1.65% |
| Guardant Health Inc EC | $46.2M | 1.48% |
| 10x Genomics Inc EC | $45.1M | 1.45% |
| Revolution Medicines Inc EC | $45.1M | 1.44% |
| Waters Corp EC | $44.5M | 1.43% |
| Oruka Therapeutics Inc EC | $41.3M | 1.32% |
| Ucb Sa EC | $41.1M | 1.32% |
| Cvs Health Corp EC | $40.2M | 1.29% |
| Gilead Sciences Inc EC | $39.1M | 1.25% |
| Boston Scientific Corp EC | $38.3M | 1.23% |
| Repligen Corp EC | $38.1M | 1.22% |
| Enliven Therapeutics Inc EC | $36.7M | 1.18% |
| Cogent Biosciences Inc EC | $35.8M | 1.15% |
| Royalty Pharma PLC EC | $35.1M | 1.12% |
| Kiniksa Pharmaceuticals International PLC EC | $34.2M | 1.10% |
| Vaxcyte Inc EC | $34.1M | 1.09% |
| Spyre Therapeutics Inc EC | $33.4M | 1.07% |
| Jazz Pharmaceuticals PLC EC | $32.4M | 1.04% |
| Moderna Inc EC | $32.1M | 1.03% |
| Xenon Pharmaceuticals Inc EC | $29.3M | 0.94% |
| Bruker Corp EC | $28.7M | 0.92% |
| Illumina Inc EC | $28.3M | 0.91% |
| Veracyte Inc EC | $27.8M | 0.89% |
| Lifestance Health Group Inc EC | $26.2M | 0.84% |
| Praxis Precision Medicines Inc. EC | $25.5M | 0.82% |
| Sartorius Stedim Biotech EC | $24M | 0.77% |
| Kymera Therapeutics Inc EC | $23.6M | 0.76% |
| Roivant Sciences Ltd EC | $21.7M | 0.70% |
| Mbx Biosciences Inc EC | $21.6M | 0.69% |
| Privia Health Group Inc EC | $21.2M | 0.68% |
| Insmed Inc EC | $20.5M | 0.66% |
| Biogen Inc EC | $20.3M | 0.65% |
| Relay Therapeutics Inc EC | $19.6M | 0.63% |
| Legend Biotech Corp EC | $18.9M | 0.61% |
| Cencora Inc EC | $18.7M | 0.60% |
| Dianthus Therapeutics Inc EC | $17.5M | 0.56% |
| Axsome Therapeutics Inc EC | $17.4M | 0.56% |
| Cg Oncology Inc EC | $16.2M | 0.52% |
| Zenas Biopharma Inc EC | $15.7M | 0.50% |
| Disc Medicine Inc EC | $15.4M | 0.49% |
| Mineralys Therapeutics Inc EC | $15.3M | 0.49% |
| Brightspring Health Services Inc EC | $14.9M | 0.48% |
| Caris Life Sciences Inc EC | $14.6M | 0.47% |
| Beone Medicines Ltd EC | $14.5M | 0.47% |
| Amylyx Pharmaceuticals Inc EC | $14.5M | 0.47% |
| Viridian Therapeutics Inc EC | $14.4M | 0.46% |
Showing top 60 of 154 holdings.
Loading...
